India's Ozempic Boom Fuels Weight Loss and Diabetes Drug Rush

Demand for weight loss and diabetes drugs like Ozempic, Wegovy and Mounjaro is soaring in India. The surge follows rising obesity and diabetes rates, with over 100 million Indians already diabetic and another 135 million prediabetic. Manufacturers are now racing to meet demand as patents near expiry and generic alternatives loom. The global market for GLP-1 drugs, including semaglutide-based treatments like Ozempic and Wegovy, is set to reach $62.83 billion by 2025. Growth is driven by increasing diabetes and obesity cases, with shortages reported in Europe and massive production expansions by Novo Nordisk. In India, Ozempic's patent on semaglutide expires in March 2024, potentially paving the way for cheaper generics. Mounjaro, another injectable weight loss drug, has already become India's top-selling medication by value since its March approval. October sales alone exceeded $11 million. Patients like Shyamanthak Kiran, a 27-year-old trader, have lost over 60 pounds in six months using it. Doctors, however, caution against over-reliance on these drugs. Rajendra Nath Dixit, a retired banker, combined oral semaglutide (Rybelsus) with diet changes and exercise to reduce his insulin dependency. Yet many patients admit they struggle to sustain lifestyle changes, making long-term drug use appealing despite side effects. Novo Nordisk is now pushing to expand Ozempic's approval in India for weight loss, though it remains officially cleared only for diabetes treatment. With diabetes and obesity rates climbing, India's demand for drugs like Ozempic and Mounjaro shows no signs of slowing. The upcoming patent expiry for semaglutide could further boost access and affordability. Meanwhile, doctors continue to stress that medication works best alongside diet and exercise—not as a standalone solution.